Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 33Breast Neoplasms 26Triple Negative Breast Neoplasms 17Prostatic Neoplasms 16Fallopian Tube Neoplasms 11Neoplasms 9Fanconi Anemia, Complementation Group D1 7Endometrial Neoplasms 7Pancreatic Neoplasms 6Glioma 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Neoplasm Metastasis 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Osteosarcoma 3Lung Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinosarcoma 3Carcinoma, Renal Cell 3Wilms Tumor 2

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2olaparib 1exemestane 1abemaciclib 1X-Rays 1Tamoxifen 1Letrozole 1Gonadotropin-Releasing Hormone 1Fulvestrant 1Fluorodeoxyglucose F18 1Estradiol 1Biopsy 1Anastrozole 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anatomic Stage III Breast Cancer AJCC v8 × olaparib × Clear all
NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Breast

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡